Alogliptin had no effect on composite events of cardiovascular death and hospital admission for heart failure in the post hoc analysis (HR 1.00, 95% CI 0.82–1.21) and results did not differ by baseline BNP concentration [82]. The gene discussed is NPPB; the disease is heart failure.